Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE...

PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases $7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. Existing investors Cambridge Enterprise, University of Cambridge Enterprise Fund...

MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AGOURA HILLS, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September...

Mateon Therapeutics Closes $2.0 Million Financing AGOURA HILLS, California, July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of...

Global Metabolism Drugs Market to Surpass US$ 9.9 Billion by 2026 – Coherent Market Insights Seattle, July 16, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global metabolism drugs market was valued at US$ 5,765.3 million in 2017 and is projected to exhibit a CAGR of...